MARKET

ENTO

ENTO

First Wave Biopharma Inc
NASDAQ
1.800
+0.029
+1.61%
After Hours: 1.750 -0.05 -2.78% 17:46 06/25 EDT
OPEN
1.730
PREV CLOSE
1.772
HIGH
1.910
LOW
1.730
VOLUME
47.13K
TURNOVER
0
52 WEEK HIGH
60.00
52 WEEK LOW
1.700
MARKET CAP
4.46M
P/E (TTM)
-0.0347
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ENTO last week (0617-0621)?
Weekly Report · 1d ago
Entero Therapeutics Executive Team Strategic Reshuffle
TipRanks · 5d ago
Weekly Report: what happened at ENTO last week (0610-0614)?
Weekly Report · 06/17 09:32
12 Health Care Stocks Moving In Wednesday's After-Market Session
Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 5.92%. Entero Therapeutics (NASdaq:ENTO) shares rose by 8.69%.
Benzinga · 06/12 20:31
12 Health Care Stocks Moving In Monday's After-Market Session
Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. LifeMD stock rose 5.81% in the same period. Losers Vicarious Surgical (NYSE:RBOT) and ProKidney stock fell 15.6% during the session.
Benzinga · 06/10 20:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Calidi Biotherapeutics shares rose 29.7% to $0.25 during Monday's pre-market session. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% during the session. Co-Diagnostics stock moved upwards by 14.07%. Sunshine Biopharma and Skye Bioscience were among the losers.
Benzinga · 06/10 12:06
Weekly Report: what happened at ENTO last week (0603-0607)?
Weekly Report · 06/10 09:32
Weekly Report: what happened at ENTO last week (0527-0531)?
Weekly Report · 06/03 09:33
More
About ENTO
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Webull offers Entero Therapeutics Inc stock information, including NASDAQ: ENTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTO stock methods without spending real money on the virtual paper trading platform.